Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07692594 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Heart and Blood Vessels Health in People With Cystic Fibrosis

Study acronym: CHi-CF
StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Jun 30, 2028 → Aug 30, 2028
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Liverpool Heart and Chest Hospital NHS Foundation Trust

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Jul 1, 2026 to Sep 1, 2026
    • Primary and study completion pushed from Jun 30, 2028 to Aug 30, 2028
    v3
  2. Notable Primary endpoint(s) modified
    • Secondary endpoints: 3 to 4
    v2
  3. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Cystic fibrosis (CF) is a disease that affects over 11,000 people in the UK. It is a genetic condition that affects many organs including the lungs, pancreas, kidneys and liver. New drugs called "modulators" have meant people with CF are now living much longer. Until recently, heart disease was rare in CF, but with the new modulators there are increasing concerns that heart disease may become a big problem in the future. This is partly to do with the drugs causing weight gain and higher blood pressure, which are risk factors for heart disease. My PhD project aims to find out whether the blood vessels and hearts of people with CF are healthy or diseased. I will then find out how the blood vessels are changing over time and work out what things are driving those changes. I will measure the health of the blood vessels and heart using an ultrasound machine to understand what the pattern of disease is like and who might be at the highest risk for heart disease in the future. I will then repeat these measurements a year later. I will compare people of different ages and with different types of disease to understand what things may help us identify heart disease as soon as possible. In the general population, doctors often use medical prediction tools to find out who is at the highest risk for heart disease. We do not know if these work for people with CF, so I will also find out whether those prediction tools are useful in CF. It is vital to understand who may be at risk for heart disease, as one of the most effective ways of treating heart disease is to prevent it from happening. This work may pave the way for future studies to test early treatment for heart disease in those people we identify might be at high risk. Early prevention treatment could reduce the risk of heart disease and ultimately improve the length and quality of life of people living with CF. This is particularly important given people with CF already have a much shorter life expectancy than the general population. In summary, this PhD project will help improve our understanding of heart disease in CF and help identify the best way forward to prevent heart disease causing health problems related to heart disease for these individuals in the future.
Trial Details
NCT Number NCT07692594
Lead Sponsor Liverpool Heart and Chest Hospital NHS Foundation Trust
Collaborators: Asthma and Lung UK, Liverpool John Moores University
Conditions
(from sponsor)
Cystic Fibrosis (CF), Cardiovascular (CV) Risk, Flow-mediated Dilation Evaluation of the Brachial Artery, Pulse Wave Analysis
Related terms Cardiovascular Diseases, Cystic Fibrosis
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov